Computer Monitor vs Augmented Reality 3MDR for PTSD PTSD: A Randomized Controlled Trial
CARE4PTSD
Computer Monitor Versus Augmented Reality: Expanding 3MDR Therapy for PTSD
1 other identifier
interventional
60
1 country
1
Brief Summary
This is a prospective randomized controlled trial comparing two ways of delivering Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) therapy for posttraumatic stress disorder (PTSD). The study seeks 60 volunteers who have PTSD and are eligible for care in the Department of Defense healthcare system. There will be 10-14 therapy sessions that are 60-90 minutes long, about once a week, and symptoms will be assessed before and after the therapy as well as 3 and 6 months after completing therapy. 3MDR asks you to choose pictures and music that are integrated into a virtual reality environment. You will be walking on a treadmill throughout each therapy session, while the therapist stands next to the treadmill and asks you questions about the pictures you chose.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 11, 2021
CompletedFirst Posted
Study publicly available on registry
February 17, 2022
CompletedStudy Start
First participant enrolled
April 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 30, 2027
July 15, 2025
July 1, 2025
4.1 years
August 11, 2021
July 14, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Clinician Administered PTSD scale for DSM5 (CAPS-5)
The primary outcome measure will be the Clinician Administered PTSD scale for DSM5 (CAPS-5), the gold standard measure for PTSD diagnosis, to assess PTSD symptom severity.
3 months
PTSD Checklist for DSM5 (PCL5)
The PTSD Checklist for DSM5 (PCL5), a well-validated 20-item self-report measure of PTSD symptom severity.
3 months
Secondary Outcomes (4)
Patient Health Questionnaire Depression module (PHQ-9)
3 months
Insomnia Severity Index (ISI)
3 months
Neurobehavioral Symptom Inventory (NSI)
3 months
Brief Resilience Scale (BRS)
3 months
Study Arms (2)
3MDR delivered via Augmented Reality Head Mounted Display
EXPERIMENTALAll participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
3MDR delivered via 34-inch curved screen high definition gaming computer monitor
ACTIVE COMPARATORAll participants will complete 10-14 treatment sessions (three preparatory sessions, 6 to 10 3MDR therapy sessions, and one concluding session), led by a therapist who has completed training and/or is experienced in the conduct of this form of therapy.
Interventions
"Walk and talk" therapy, walking on a treadmill while talking with a therapist about self-chosen pictures representative of one's trauma; 3MDR also includes some features of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR) therapy.
Eligibility Criteria
You may qualify if:
- Service member, veteran, retiree, or DEERS-eligible dependent, male or female, at least 18 years or older
- Diagnosis of PTSD, as confirmed by the CAPS-5
- Able to ambulate with contact guard assistance or less, and walk unassisted on a treadmill, at a normal pace, for up to 90 minutes continuously
You may not qualify if:
- History of epilepsy or a seizure disorder, other than febrile seizures that occurred during childhood and have not recurred since
- History of a psychotic disorder, bipolar disorder, or active suicidal or homicidal ideation
- Use of benzodiazepines on a regular basis within the previous 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Uniformed Services University
Bethesda, Maryland, 20814, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Roy, MD, MPH
Unformed Services University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
August 11, 2021
First Posted
February 17, 2022
Study Start
April 30, 2023
Primary Completion (Estimated)
May 31, 2027
Study Completion (Estimated)
October 30, 2027
Last Updated
July 15, 2025
Record last verified: 2025-07